Literature DB >> 3194897

Factor X-activating activity in normal and malignant colorectal tissue.

J L Francis1, K el-Baruni, O S Roath, I Taylor.   

Abstract

The factor X-activating activity (FXAA) of homogenates from human colorectal tumours and corresponding normal colonic mucosa from the same patients was assessed with a specific chromogenic substrate technique. FXAA was detected in all normal and tumour tissue tested, but was significantly higher in tumour tissue. The procoagulant activity was inhibited by DFP, but was unaffected by iodoacetamide and mercuric chloride. FXAA was largely abolished by prior incubation of both normal and tumour tissue homogenates with a rabbit anti-human factor VII serum, but was greatly enhanced by the addition of purified factor VII. FXAA was partially adsorbed on to aluminium hydroxide and almost completely abolished by treatment with barium citrate. It is concluded that the FXAA of both normal and malignant colorectal tissue is the result of tissue factor-factor VII interaction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3194897     DOI: 10.1016/0049-3848(88)90080-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

Review 1.  Tissue factor as a tumor procoagulant.

Authors:  L V Rao
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

2.  The effect of Warfarin and factor VII on tissue procoagulant activity and pulmonary seeding.

Authors:  J L Francis; N Carty; M Amirkhosravi; M Loizidou; A Cooper; I Taylor
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

Review 3.  Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment.

Authors:  Norbaini Binti Abdol Razak; Gabrielle Jones; Mayank Bhandari; Michael C Berndt; Pat Metharom
Journal:  Cancers (Basel)       Date:  2018-10-11       Impact factor: 6.639

4.  Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.

Authors:  A S Adamson; P Luckert; M Pollard; M E Snell; M Amirkhosravi; J L Francis
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.